Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses is a research paper published in Diabetes Therapy (2021). On theSindex it has a DataRank of 0.968. It has been cited 20 times, with 20 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.457
From this paper's citation signal
Citation Network Contribution
0.511
From 14 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 20 citers.
NCATS NIH HHS
Grant: UL1 TR002489
NIDDK NIH HHS
Grant: P30 DK124723
National Institutes of Health
Grant: 3UL1TR002489-02S1
North Carolina Translational and Clinical Science Institute (NC TraCS)
National Institutes of Health
Grant: 1P30DK124723-01
North Carolina Diabetes Research Center
Novo Nordisk A/S
FWCI
2.29
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Oral Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
Oral Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses